Edigene

Boya Gene was founded in 2015 and currently operates four platforms focused on gene editing technology, with a dedication to advancing research and development projects for genetic diseases and tumors into clinical applications. The platforms include in vitro cell gene editing therapy for hematopoietic stem cells and T cells, in vivo gene editing therapy based on RNA single-base editing technology, and a high-throughput genome editing screening platform for targeted drug development. In 2018, Boya Gene established a clinical transformation application base meeting GMP standards in Nansha District, Guangzhou. Medigene AG is a biotechnology company listed on the Frankfurt (MDG1, prime standard) stock exchange and headquartered in Martinsried near Munich, Germany. The company focuses on developing highly innovative cellular therapies for various types and stages of cancer, with candidates in clinical and pre-clinical development. Medigene specializes in personalized T cell-based immunotherapies.